Lakefront Biotherapeutics (LKFT) Accounts Payables (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Accounts Payables for 13 consecutive years, with $109.0 million the latest figure, recorded in Q1 2026.

• Quarterly Accounts Payables fell 43.31% year-over-year to $109.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $109.0 million (down 43.31% YoY) and the FY2025 annual result came in at $119.1 million, up 5.84% from the prior year.
• Accounts Payables eased to $109.0 million in Q1 2026 per LKFT's latest filing, from $119.1 million in the prior quarter.
• Over the last five years, Accounts Payables for LKFT reached as high as $192.3 million in Q1 2025 and fell as low as $109.0 million in Q1 2026.
• A 5-year average of $145.2 million and a median of $151.6 million in 2025 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2025 — Accounts Payables climbed 16.07% — and 2026, when it plunged 43.31%.
• Year by year, Accounts Payables stood at $169.2 million in 2022, then retreated by 9.06% to $153.9 million in 2023, then dropped by 26.87% to $112.5 million in 2024, then increased by 5.84% to $119.1 million in 2025, then declined by 8.49% to $109.0 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $109.0 million, $119.1 million, and $114.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.